Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Tammy Schuler
Observed names:
T Schuler,
T.A Schuler
Institution:
Cardinal Health (United States)
Observed institution:
Cardinal Health (United States)
ORCID:
0000-0003-3173-5918
Observed ORCID:
0000-0003-3173-5918
OpenAlex ID:
A5079109750
Real-World Use of Ruxolitinib in Patients with Myelofibrosis and Anemia or Thrombocytopenia at Diagnosis
2024
·
Jingbo Yu
, Emily Bland
, et al.
·
Acta Haematologica
·
7
PDF
The Use of Fedratinib for Myelofibrosis As a Potential Bridge to Hematopoietic Stem Cell Transplantation after Ruxolitinib Failure: Real-World Assessment of Treatment Characteristics and Spleen, Symptom, and Hematologic Response
2022
·
John Mascarenhas
, Claire Harrison
, et al.
·
Blood
·
2
Real-World Use of Ruxolitinib in Patients with Myelofibrosis Who Had Anemia or Thrombocytopenia at US Community Practices
2022
·
Srdan Verstovsek
, Jingbo Yu
, et al.
·
Blood
·
2
Outcomes in patients with resected stage IIIA melanoma treated with adjuvant nivolumab or monitored with observation: A real-world study.
2022
·
Anna C. Pavlick
, Asim Amin
, et al.
·
Journal of Clinical Oncology
·
2
Does Physician Documentation of Patients’ Prostate-Specific Antigen Doubling Time Affect Treatment Decisions in High-Risk Biochemically Recurrent Prostate Cancer?
2026
·
Alicia K. Morgans
, Maelys Touya
, et al.
·
Clinical Genitourinary Cancer
·
1
Characteristics and treatment (Tx) patterns (TxP) of high-risk biochemically recurrent (HR-BCR) non-metastatic castration-sensitive prostate cancer in the real-world by race, age, and prostate-specific antigen (PSA) doubling time (PSADT).
2024
·
Alicia K. Morgans
, Lisa Mucha
, et al.
·
Journal of Clinical Oncology
·
1
PDF
The Use of Fedratinib (FEDR) for Myelofibrosis (MF) As a Potential Bridge to Hematopoietic Stem Cell Transplantation (HSCT) after Ruxolitinib (RUX) Failure: Real-World Assessment of Treatment Characteristics and Spleen, Symptoms, and Hematologic Response
2024
·
John Mascarenhas
, Claire Harrison
, et al.
·
Transplantation and Cellular Therapy
·
1
RWD95 Comparing Representativeness of Race and Ethnicity in Real-World Evidence, Randomized Clinical Trial, and Surveillance, Epidemiology, and End Results (SEER) Cancer Patient Data
2023
·
A. Balanean
, D. Gentile
, et al.
·
Value in Health
·
1
Hsd115 Treatment After Car T-cell Therapy Failure in Diffuse Large B-cell Lymphoma: Hematologist/oncologists’ Perspectives on Odronextamab and Results From the Elm-1 Study
2026
·
Sarah Lucht
, Blaise Nwotchouang
, et al.
·
Value in Health
PDF
Msr113 Physician-led Chart Abstraction (plca) in Oncology: Advancing Fda Fit-for-use Real-world Data for Heor Decision-making
2026
·
Alex C. Wu
, Madison Brown
, et al.
·
Value in Health
Description and management strategies of prespecified treatment emergent adverse events (TEAEs) amongst patients (pts) treated with 1L enfortumab vedotin (EV) + pembrolizumab (P) for la/mUC in a real-world setting.
2026
·
David Michael Gill
, Lisa Mucha
, et al.
·
Journal of Clinical Oncology
CO40 Real-World Patient Characteristics and Treatment Patterns in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients With Long-Term Survivorship
2025
·
Tammy Schuler
, Puja Aggarwal
, et al.
·
Value in Health
Real-World Patient Characteristics and Treatment Patterns in ALL Survivors with Relapsed/Refractory ALL
2024
·
Tammy Schuler
, Puja Aggarwal
, et al.
·
Blood
PDF
RWD18 Age Comparisons across Real-World Evidence Research, Randomized Clinical Trials, and Surveillance, Epidemiology, and End Results (SEER) in Advanced Cancer
2023
·
T.A Schuler
, A. Balanean
, et al.
·
Value in Health
PDF
Prevalence of historical medical conditions or comorbidities with potential role in clinical decision making related to suitability of immuno-oncologic plus IV antiangiogenic therapy in newly diagnosed first-line unresectable hepatocellular carcinoma in the United States.
2023
·
Tammy Schuler
, Leonardo Passos Chaves
, et al.
·
Journal of Clinical Oncology
CO5 Completeness of Real-World Data (RWD) in Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in United States (US) Community Oncology/Hematology Practices (CH/OS)
2022
·
B Feinberg
, A Klink
, et al.
·
Value in Health
PDF
CO99 Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Utilization Patterns for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Among United States (US) Community Hematologists/Oncologists (CH/OS)
2022
·
B Feinberg
, A Klink
, et al.
·
Value in Health
PDF
Show more works
View as search
Works count:
17
Citation count:
17
H-index:
2
I10-index:
Year
Topic
Type